Becton Dickinson Pays $22M To Settle Syringe Antitrust Suits

Law360, Los Angeles (August 1, 2013, 8:24 PM EDT) -- Becton Dickinson & Co. has struck a $22 million settlement agreement with hospitals and pharmacies whose class actions accused the New Jersey-based medical technology company of stifling competition from other hypodermic product makers, the company said in a Tuesday filing with the U.S. Securities and Exchange Commission.

Under the terms of the proposed settlement, BD will pay $22 million into a settlement fund in exchange for a release by all potential members of the class of indirect purchasers of BD products, which alleged the company controlled...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.